ATE473758T1 - Her-2/neu multipeptidimpfstoff - Google Patents

Her-2/neu multipeptidimpfstoff

Info

Publication number
ATE473758T1
ATE473758T1 AT06007834T AT06007834T ATE473758T1 AT E473758 T1 ATE473758 T1 AT E473758T1 AT 06007834 T AT06007834 T AT 06007834T AT 06007834 T AT06007834 T AT 06007834T AT E473758 T1 ATE473758 T1 AT E473758T1
Authority
AT
Austria
Prior art keywords
new
vaccine
multipeptide vaccine
multipeptide
neu
Prior art date
Application number
AT06007834T
Other languages
English (en)
Inventor
Christoph Zielinski
Otto Schreiner
Hubert Pehamberger
Heimo Breiteneder
Ursula Wiedermann
Original Assignee
Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh filed Critical Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh
Application granted granted Critical
Publication of ATE473758T1 publication Critical patent/ATE473758T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06007834T 2006-04-13 2006-04-13 Her-2/neu multipeptidimpfstoff ATE473758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007834A EP1844788B1 (de) 2006-04-13 2006-04-13 HER-2/neu Multipeptidimpfstoff

Publications (1)

Publication Number Publication Date
ATE473758T1 true ATE473758T1 (de) 2010-07-15

Family

ID=37110206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06007834T ATE473758T1 (de) 2006-04-13 2006-04-13 Her-2/neu multipeptidimpfstoff

Country Status (9)

Country Link
US (1) US20090269364A1 (de)
EP (2) EP1844788B1 (de)
AT (1) ATE473758T1 (de)
AU (1) AU2007237491B2 (de)
CA (1) CA2649013C (de)
DE (1) DE602006015421D1 (de)
ES (1) ES2348312T3 (de)
IL (1) IL194162A (de)
WO (1) WO2007118660A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
CA2743904A1 (en) * 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
KR20130127547A (ko) * 2009-07-30 2013-11-22 화이자 백신스 엘엘씨 항원성 타우 펩타이드 및 이의 용도
EP2292258A1 (de) * 2009-08-18 2011-03-09 Pevion Biotech Ltd. Multiepitop-Impfstoff für Her2/neu-assoziierten Krebs
CN108864291A (zh) * 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
WO2013116656A1 (en) * 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
KR102372615B1 (ko) 2015-04-17 2022-03-08 바이오라이프 사이언스 큐엘디 리미티드 백신 조성물 및 그의 용도
EP3297658A1 (de) * 2015-05-18 2018-03-28 OncoQR ML GmbH Immunogene her2/neu-zusammensetzung
CN110709094A (zh) 2017-02-03 2020-01-17 威斯康星州医药大学股份有限公司 Kras肽疫苗组合物及其使用方法
AU2018383096A1 (en) 2017-12-11 2020-06-11 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
WO2021002855A1 (en) * 2019-07-02 2021-01-07 Virago Vax Inc. Mammary tumor virus vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117165A (ja) * 1991-10-24 1993-05-14 Masakazu Ueda 抗癌剤
AU6620300A (en) * 1999-08-03 2001-02-19 Ohio State University, The Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
EP1236740B1 (de) * 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US20030082630A1 (en) * 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains

Also Published As

Publication number Publication date
US20090269364A1 (en) 2009-10-29
CA2649013C (en) 2017-05-02
WO2007118660A3 (en) 2007-12-13
EP2004218A2 (de) 2008-12-24
AU2007237491B2 (en) 2012-11-01
WO2007118660A2 (en) 2007-10-25
AU2007237491A1 (en) 2007-10-25
DE602006015421D1 (de) 2010-08-26
ES2348312T3 (es) 2010-12-02
EP1844788B1 (de) 2010-07-14
IL194162A (en) 2014-04-30
IL194162A0 (en) 2011-08-01
EP1844788A1 (de) 2007-10-17
CA2649013A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE473758T1 (de) Her-2/neu multipeptidimpfstoff
PH12014501083A1 (en) Anticancer fusion protein
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
ATE387233T1 (de) Schutzhülse für nadeln mit absatz
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
MX337436B (es) Proteina de funsion anticancer.
NZ611108A (en) Methods of treating fgf21-associated disorders
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
BR112014019901A2 (pt) proteínas de fator viii recombinante
DOP2010000325A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201000327A1 (ru) Белок
EA201000865A1 (ru) Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
CY1116269T1 (el) Χρηση μιας πρωτεϊνης απο λουπινο
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
WO2008093058A3 (en) Peptides and their use
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
ATE538660T1 (de) Verfahren zur herstellung eines weizenproteinhydrolysats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1844788

Country of ref document: EP